Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has announced a definitive agreement to acquire APEIRON Biologics AG for $100 million in cash. APEIRON holds royalty rights to QARZIBA® (dinutuximab beta), a treatment for high-risk neuroblastoma. In addition to the initial payment, Ligand…
Epsilogen Receives CTA Approval for Phase Ib Trial of MOv18 IgE in Platinum-Resistant Ovarian Cancer Epsilogen has announced that it has received Clinical Trial Authorization (CTA) approval for a Phase Ib study to evaluate the efficacy of MOv18 IgE in…
Neuranics, a pioneering deep tech startup based in Glasgow, proudly announced its prestigious accolade as the Deep Tech Investment of the Year at the UK Angel Investment Awards. The ceremony, held at the Science Museum London, underscored Neuranics’ rapid ascent…
Axena Health Secures Expanded Insurance Coverage for Leva Pelvic Health System Axena Health, Inc. (Axena Health) has achieved a significant milestone in expanding insurance coverage for its Leva® Pelvic Health System. Two major health plans in Pennsylvania and North Dakota…
The latest addition to ResearchAndMarkets.com’s offerings is the “Hospital Care Collaboration and Licensing Deals 2016-2024” report, now fully revised and updated. This comprehensive report delves into hospital care deals spanning the years 2016 to 2024, providing unprecedented insights into collaborations…
The “Collaboration Deals in Pharmaceuticals 2019-2024” report is now available on ResearchAndMarkets.com. This report offers a detailed analysis of collaboration deals in the pharmaceutical industry, explaining why and how companies enter these deals. Updated to include data from 2019 to…
The ‘In Vitro Diagnostic Collaboration and Licensing Deals 2016-2024’ report offers an extensive analysis and unprecedented access to collaboration and licensing agreements in the global biopharma industry. Updated and meticulously compiled, this report delves into the intricate details of over…
BenevolentAI (Euronext Amsterdam: BAI), a pioneering force in applying advanced artificial intelligence (AI) to expedite biopharma drug discovery, has announced changes to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board…
AstraZeneca’s Marketing Authorisation Application (MAA) for sipavibart has been accepted under the accelerated assessment procedure by the European Medicines Agency (EMA) for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients. Sipavibart is an investigational long-acting antibody designed to provide…
AbbVie announced today that Robert A. Michael has taken on the role of Chief Executive Officer (CEO) and joined the company’s Board of Directors, effective immediately. As previously announced, Mr. Michael succeeds Richard A. Gonzalez, who has been the CEO…
Roche’s PiaSky Receives Positive CHMP Opinion for PNH Treatment in EU Today, Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended PiaSky® (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). PiaSky,…
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has launched Allē Payment Plans, powered by Cherry, to offer consumers the ability to pay for aesthetic treatments and products, including BOTOX® Cosmetic (onabotulinumtoxinA) and the JUVÉDERM® Collection of Fillers, over time.…